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ABSTRACT
Oncogene-induced senescence (OIS), provoked in
response to oncogenic activation, is considered an
important tumor suppressor mechanism. Long non-
coding RNAs (lncRNAs) are transcripts longer than
200 nt without a protein-coding capacity. Functional
studies showed that deregulated lncRNA expres-
sion promote tumorigenesis and metastasis and that
lncRNAs may exhibit tumor-suppressive and onco-
genic function. Here, we first identified lncRNAs that
were differentially expressed between senescent and
non-senescent human fibroblast cells. Using RNA
interference, we performed a loss-function screen
targeting the differentially expressed lncRNAs, and
identified lncRNA-OIS1 (lncRNA#32, AC008063.3 or
ENSG00000233397) as a lncRNA required for OIS.
Knockdown of lncRNA-OIS1 triggered bypass of
senescence, higher proliferation rate, lower abun-
dance of the cell-cycle inhibitor CDKN1A and high
expression of cell-cycle-associated genes. Subcellu-
lar inspection of lncRNA-OIS1 indicated nuclear and
cytosolic localization in both normal culture condi-
tions as well as following oncogene induction. In-
terestingly, silencing lncRNA-OIS1 diminished the
senescent-associated induction of a nearby gene
(Dipeptidyl Peptidase 4, DPP4) with established role
in tumor suppression. Intriguingly, similar to lncRNA-
OIS1, silencing DPP4 caused senescence bypass,
and ectopic expression of DPP4 in lncRNA-OIS1
knockdown cells restored the senescent phenotype.
Thus, our data indicate that lncRNA-OIS1 links onco-
genic induction and senescence with the activation
of the tumor suppressor DPP4.
INTRODUCTION
Next-generation sequencing (NGS) and microarray tech-
nologies uncovered thousands of long non-coding RNAs
(lncRNAs) encoded in the human genome (1,2). The ma-
jority of those lncRNAs are transcribed and processed in
a similar manner to mRNAs, however, lack protein-coding
potential (3,4). Although it is still unclear how many of
those lncRNAs have a significant biological function, some
of them have been found to be crucial players in the regu-
lation of cellular processes such as proliferation, differenti-
ation or development, as well as in a progression of a vari-
ety of human diseases including cancer (5–10). It has been
shown that lncRNAs are key determinants of epigenetic
regulation, modulation of chromatin structure, scaffold-
ing or decoy function of mRNAs and post-transcriptional
mRNA regulation (11–15).Gene regulation by lncRNAs
can be a result of cis-action on nearby genes, or in trans
by modulating mRNA stability, mRNA translation, or mi-
croRNA and RNA-binding-protein function (16–23).
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Cellular senescence was initially defined by Hayflick in
1965 as the limited lifespan of primary human fibroblasts
in culture (24). It is a state of irreversible growth arrest
which can be induced by different stimuli such as telom-
ere shortening, DNA damage, oxidative stress or onco-
gene activation (25). Serrano et al., were the first to ob-
serve that primary human and mouse fibroblasts enter
senescence following the induction of oncogenic RAS, a
process termed oncogene-induced senescence (OIS) (26).
Cellular senescence has been studied most extensively as
a strong tumor-suppressive mechanism against the emer-
gence of oncogenes (27). Moreover, there is evidence in-
dicating for a role of senescence in age-related condi-
tions and diseases, including cancer, cardiovascular dis-
eases, neurodegeneration, diabetes, sarcopenia and declin-
ing immune function in the elderly (28–32). In contrast,
senescent cells can also contribute to tumorigenesis by se-
creting interleukins (e.g. IL-6, IL-8 and IL-1a), metallopro-
teases (e.g. MMP-1 and MMP-3) and other cytokines (e.g.
granulocyte-macrophage colony-stimulating factor (GM-
CSF)), as part of the senescence-associated secretory phe-
notype (25,30,33–37). Therefore, senescencemay either sup-
press or promote tumor progression depending on the con-
text where it occurs (38,39). Given the impact of senescence
on human physiology and pathology, it is of interest to un-
derstand the molecular mechanisms underlying senescence
in order to utilize it for diagnosis and therapy.
A number of factors have been implicated in regulat-
ing senescence, including transcription factors, RNA bind-
ing proteins and microRNAs, such as p53, Ets (40), HuR
(41), AUF1 (42) and TTP (43), and miR-377 (44), miR-22
(45). In contrast, despite increasing interest in the expres-
sion and function of lncRNAs, their possible implication
in senescence remains largely unexplored. Recent works in-
dicated a role of MIR31HG and SALNR in senescence
(46,47), but a focused functional genetic screen was not de-
scribed before. We therefore sought to identify senescence-
associated lncRNAs using our established cellular system
that induces senescence in primary human BJ fibroblasts
(48). Using transcriptomic profiling we identified a num-
ber of differentially expressed lncRNAs following onco-
gene induction. Next, using functional screen, we discov-
ered that one of the lncRNAs whose expression was in-
duced upon oncogenic stress––lncRNA-OIS1––is required
for OIS. We demonstrate that lncRNA-OIS1 is required for
senescence by controlling a nearby DPP4 gene with a tu-
mor suppressive activity. Collectively, our results provide a
new lncRNA-mediated regulatory pathway for controlling
DPP4 during OIS. Our findings support the role of lncR-
NAs as transcriptional regulators in critical processes such
as cellular senescence and a potential role in cancer.
MATERIALS AND METHODS
Cell culture, transfection, retroviral and lentiviral transduc-
tion
BJ/ET/RasV12, TIG3/ET/RASV12, Ecopack 2 and
HEK293-T cells were cultured in Dulbecco’s modified
Eagle’s medium (Gibco), supplemented with 10% fetal calf
serum (FCS) (Hyclone) and 1% penicillin/streptomycin
(Gibco). Senescence was induced by treatment with 100
nM 4-OHT (Sigma) for 14 days. Retroviruses were made
by calcium phosphate transfection of Ecopack 2 cells and
harvest at 40 and 64 h later. Lentiviruses were made by
polyethylenimine (PEI) transfection of HEK293T.Medium
was refreshed after 16 h and collect the lentivirus by fil-
tering through a 0.45 m membrane (Milipore Steriflip
HV/PVDF) 40 h post-transfection and stored at −80◦C.
Cells were selected with the proper selection medium 48 h
after transduction for at least 4 days until no surviving cells
remained in the no-transduction control plate.
RNA-seq and analysis
RNA-seq samples were processed with TruSeq RNA li-
brary prep kit v2 (Illumina) and sequenced in a HiSeq
2500 (Illumina). Sequenced reads were aligned to the hu-
man genome (hg19) using TopHat2 (49) and gene expres-
sion levels were counted using HTseq (50) and normalized
using quantile normalization. To avoid inflation of lowly ex-
pressed genes among the genes called as differentially ex-
pressed, we applied a dynamic cut-off which takes into ac-
count that technical variation varies with expression level.
Specifically, in the comparison between two conditions, we
divided the genes into 20 bins according to their average ex-
pression level, and calculated the standard deviation (SD)
of fold-changewithin each bin.Genes whose expressionwas
changed by at least 1.75-fold and this fold-changewas above
the bin’s 1.75 SD (dashed curve in Figures 1B and 3B) were
called as differentially expressed. To further avoid false pos-
itive calls among lowly expressed genes we set a floor level
of five counts (i.e. any level below five was set to five). Func-
tional enrichment analysis was done using DAVID (51).
Global characterization of pathways that were deregulated
upon knockdown of lncRNA-OIS1 was done using gene set
enrichment analysis (GSEA) (52).
In situ hybridization
In situ hybridization (ISH) was performed using double-
FAM labeled locked nucleic acid (LNA) probes (Exiqon) as
described previously (53). Briefly, cells were fixed, perme-
abilized and pre-hybridized in hybridization buffer and then
hybridized at 55◦C for 1 h with LNA probes for lncRNA-
OIS1: 5-TTGAAAACCCATCACTCCT-3, or with a
scramble probe 5-TGTAACACGTCTATACGCCCA-3
as negative control, all at 25 nM. Cells were subsequently
incubated with 3% hydrogen peroxide to block potential
endogenous peroxidase, and then probes were detected
with peroxidase-conjugated anti-fluorescein-Ab (Roche
applied Sciences) diluted 1:400 followed by addition of
Cy3-labeled TSA substrate for 10 min (Perkin Elmer).
All cells were mounted with ProLong®GoldAntifade
Mountant containing DAPI nuclear stain (ThermoFisher
Scientific). Images were acquired using a Zeiss Axio Imager
Z1 epi-fluorescence microscope equipped with an Axio-
CamMRm CCD camera and a Plan-APOCHROMAT
63×/1.4 objective (Zeiss). Within the same experiment,
images were acquired at the same exposure conditions.
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Figure 1. shRNAs screen identifies a lncRNA required for OIS. (A) A screening strategy of detecting functional lncRNAs. (B) RNA-seq comprehensively
identified differentially expressed transcripts (mRNAs and lncRNAs) in senescent cells (treated with 4-OHT for 14 days) compared to untreated cells. (C)
Ribosome profiling confirmed that the identified OIS lncRNAs have no protein coding capacity. Shown are selected examples and GAPDH as control.
(D) The functional genetic screen procedure. NGS, next-generation sequencing. (E) Enrichment score calculated for each shRNA vector based on its
prevalence in the pool, harvested after 4 weeks of tamoxifen (4-OHT) treatment (RASv12 induction), relative to its prevalence in the T0 pool. The plot
shows the distribution of standardized enrichment scores (Z-scores) for the entire shRNA library.
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BrdU proliferation assay
BJ and TIG3 Cells were pulsed for 3 h with 30 M bro-
modeoxyuridine (BrdU, Sigma), washed two times with
phosphate-buffered saline (PBS) and then fixed with 4%
formaldehyde, wash two times with PBS and treated with
5M HCl/0.5% Triton to denature DNA and neutralized
with 0.1M Na2B4O7, incubated with anti-BrdU (Dako) for
2 h in RT after 30 min blocking with 3% bovine serum albu-
min (BSA) in 0.5% Tween PBS, washed in blocking buffer
(PBS, Tween 0.5%, 3% BSA) three times, and finally in-
cubated with FITC-conjugated anti-mouse Alexa FLOUR
488 secondary antibody (Dako) for 1 h, washed three times,
stained with propidium iodide for 30 min. BrdU incorpo-
ration was measured by immunofluorescence (at least 300
cells were scored for each condition).
Senescence-associated -galactosidase (SA--Gal) assay
BJ and TIG3 cells were transduced with different shRNAs
constructs, plated in triplicate and treated with 100 nM 4-
OHT for 14 days. -galactosidase activity was determined
by using the kit (Cell Signaling), and at least 300 cells were
analyzed for each condition.
Ribosome profiling (Ribo-seq)
BJ Cells were treated with cycloheximide (100 g/ml) for 5
min, and lysed 20 mM Tris–HCl, pH 7.8, 100 mM KCl, 10
mMMgCl2, 1% Triton X-100, 2 mM dithiothreitol (DTT),
100 g/ml cycloheximide, 1× complete protease inhibitor.
Lysates were centrifuged at 1300 g and the supernatant
was treated with 2 U/l of RNase I (Invitrogen) for 45
min at room temperature. Lysates were fractionated on
a linear sucrose gradient (7–47%) using the SW-41Ti ro-
tor at 36 000 rpm for 2 h. Fractions enriched in mono-
somes were pooled and treated with proteinase K (Roche,
Mannheim, Germany) in a 1% sodium dodecyl sulphate
(SDS) solution. Released RNA fragments were purified us-
ing Trizol reagent and precipitated in the presence of glyco-
gen. For libraries preparation, RNA was gel-purified on
a denaturing 10% polyacrylamide urea (7 M) gel. A sec-
tion corresponding to 30–33 nt, the region where most of
the ribosome-protected fragments are comprised, was ex-
cised, eluted and ethanol precipitated. The resulting frag-
ments were 3′-dephosphorylated using T4 polynucleotide
kinase (New England Biolabs Inc. Beverly, MA, USA) for 6
h at 37◦C in 2-(N-morpholino) ethanesulfonic acid (MES)
buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10
mM -mercaptoethanol, 300 mM NaCl). 3′ adaptor was
added with T4 RNA ligase 1 (New England Biolabs Inc.
Beverly, MA, USA) for 2.5 h at 37◦C. Ligation products
were 5′-phosphorylated with T4 polynucleotide kinase for
30 min at 37◦C. 5′ adaptor was added with T4 RNA ligase
1 for 18 h at 22◦C. The library was sequenced in illumina
HiSeq2000 machine. The data were analyzed as described
(54).
GRO-seq
Briefly, 5 × 106 nuclei were isolated and incubated 5 min
at 30◦C with equal volume of reaction buffer (10 mM Tris–
Cl pH 8.0, 5 mM MgCl2, 1 mM DTT, 300 mM KCL, 20
units of SUPERase In, 1% sarkosyl, 500 M adenosine
triphosphate (ATP), Guanosine triphosphate (GTP) and
Br-Uridine triphosphate (UTP), 0.2 M CTP+32P Cyti-
dine triphosphate (CTP)) for the nuclear run-on. The re-
action was stopped and total RNA was extracted with Tri-
zol LS (Invitrogen) according to themanufacturer’s instruc-
tions. RNA was fragmented using fragmentation reagents
(Ambion) and the reaction was purified through p-30
RNase free spin column (BioRad). BrU-labeled RNA was
immunoprecipitated with anti-BrdU agarose beads (Santa
Cruz), washed one time in binding buffer, one time in low
salt buffer (0.2 × SSPE, 1 mM ethylenediaminetetraacetic
acid (EDTA), 0.05% Tween-20), one time high-salt buffer
(0.25 × SSPE, 1 mM EDTA, 0.05% Tween-20, 137.5 mM
NaCl) and two times in TET buffer (TE with 0.05% Tween-
20). RNA was eluted with elution buffer (20 mMDTT, 300
mM NaCl, 5 mM Tris–Cl pH 7.5, 1 mM EDTA and 0.1%
SDS) and isolated with Trizol LS. After the binding step,
BrU-labeled RNAwas treated with tobacco acid pyrophos-
phatase (Epicenter) to remove 5′-methyl guanosine cap, fol-
lowed by T4 polynucleotide kinase (PNK; NEB) to remove
3′-phosphate group. BrU-containing RNAwas treated with
T4 PNK again at high pH in the presence of ATP to add
5′-phosphate group. The reaction was stopped and RNA
was extracted with Trizol LS. Sequencing libraries were
prepared using TruSeq Small RNA kit (Illumina) follow-
ing manufacturer’s instructions. Briefly, end-repaired RNA
was ligated to RNA 3′ and 5′ adapters, followed by RT-
PCR amplification. cDNA was purified using Agencourt
AMPure XP (Beckman Coulter) and amplified by poly-
merase chain reaction (PCR) for 12 cycles. Finally, ampli-
cons were cleaned and size-selected using Agencourt AM-
Pure XP (Beckman Coulter), quantified in a Bioanalyzer
2100 (Agilent), and sequenced in a HiSeq 2500 (Illumina).
Sequenced reads were aligned to the human genome (hg19)
using bowtie2 (55).
RNA isolation, reverse-transcription and quantitative real-
time PCR (qPCR)
Total RNA was extracted by using TRIsure (Bioline)
reagent and following the manufacturer’s protocol. cDNA
was produced with SuperScript III (Invitrogen) using 4
g of total RNA per reaction. qPCR reaction was per-
formed with SYBR green IMaster mix in a LightCycler 480
(Roche). Primers used in qPCR are listed in Supplementary
Table S5.
Western blot analysis
Whole-cell lysates were prepared as previously described
(56). Membranes were immunoblotted with the follow-
ing antibodies: CDKN1A (Sc-397, Santa Cruz; 1: 1000),
HRAS (C-20, SantaCruz; 1: 1000),DPP4 (ab28340, abcam;
1: 2000), GAPDH (Sc-47724, Santa Cruz; 1: 5000). Protein
bands were visualized using corresponding secondary anti-
bodies (Dako) and ECL reagent (GE Healthcare).
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Chromosome conformation capture combined with sequenc-
ing (4C-seq)
Briefly, BJ cells were treated with or without 4-OHT for 14
days and 107 of cells for each condition were harvested and
we performed 4C as previously described (57). An adapted
two-step 4C-PCR was performed as previously described
(58) to introduce template specific indexes. We had two
viewpoints and used the following primers in the first PCR:
vp1 forward
AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTCTTTGCTA
CTCTGTGAGATC
vp1 reverse
ACTGGAGTTCAGACGTGTGCTCTTCCGATCTA
TAGGGCTCTGGAGTCAG
vp2 forward
AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTGTATTTCT
CTAGCTGGGATC
vp2 reverse
ACTGGAGTTCAGACGTGTGCTCTTCCGATCAA
CCGTAAAGTCTTCGCTC
Weused the forward primers from the first PCRand com-
bined the following reverse primers for the second PCR:
BJ – 4-OHT rep1
CAAGCAGAAGACGGCATACGAGAT CGTGAT
GTGACTGGAGTTCAGACGTGTGCT
BJ– 4-OHT rep2
CAAGCAGAAGACGGCATACGAGAT GCCTAA
GTGACTGGAGTTCAGACGTGTGCT
BJ + 4-OHT rep1
CAAGCAGAAGACGGCATACGAGAT GGAACT
GTGACTGGAGTTCAGACGTGTGCT
BJ + 4-OHT rep2
CAAGCAGAAGACGGCATACGAGAT GCGGAC
GTGACTGGAGTTCAGACGTGTGCT
LncRNA-OIS1 expression analysis in tumors
Gene expression data was obtained from the TCGA Data
Portal (https://tcga-data.nci.nih.gov). We selected those
cancer types with transcriptome data available for at least
five normal and five tumor samples, belonging to phe-
notypes ‘solid tissue normal’ and ‘primary solid tumor’,
respectively. Lowly expressed genes (genes with raw read
counts in less than half the normal samples and half the
tumor samples) were removed within each cancer type
data. Differential expression analysis was carried out with
R/Bioconductor package limma (59) using voom nor-
malization (60). Pearson correlation calculation was car-
ried out using normalized gene expression values, also in
R/Bioconductor.
RESULTS
Genome-wide identification of lncRNAs responsive to OIS
To identify lncRNAs with a role in OIS, we used the model
of primary human BJ fibroblasts expressing hTERT and
4-OH-tamoxifen (4-OHT)-inducible oncogenic H-RasV12
(BJ/ET/RasV12ER cells) (48). RNA sequencing (RNA-
seq) in senescent cells and non-senescent control cells re-
vealed senescence-associated differentially expressed tran-
scripts (Figure 1B). Of those transcripts, we found 34 and 6
lncRNAs upregulated and downregulated respectively dur-
ingOIS (Supplementary Table S1). Ribosome profiling con-
firmed the non-coding nature of these RNAs (Figure 1C).
We also confirmed by qRT-PCR the induction of some
lncRNAs following H-RasV12 induction (Supplementary
Figure S1A).
A focused loss-of-function screen for lncRNAs required for
OIS identifies lncRNA-OIS1.
To examine possible causal roles for lncRNAs inOIS, we de-
veloped RNAi tools to target the 40 lncRNAs that were dif-
ferentially expressed in OIS. We generated a pooled library
consisting of five different shRNAs against each lncRNA,
and included four non-targeting shRNAs as negative con-
trols, as well as two positive control shRNAs targeting
BRD7––a gene identified as a tumor suppressor in OIS (48)
(Supplementary Table S2). We transduced cells with three
independent retroviral pools of the shRNAs library, and fol-
lowing puro selection harvested half of each cell population
as control (T0, Time 0).We cultured the rest of the cells with
4–OHT treatment for 4 weeks, then harvested the cells (T4,
Time 4 weeks) and performed NGS to identify shRNAs en-
riched in the final populations (T4) compared to the initial
(T0) pool (Figure 1D).
Our screen detected the positive control shRNAs against
BRD7, as well as few shRNAs targeting different lncRNAs
enriched in the RAS-induced cell populations, suggesting
that the knockdown of these lncRNAs conferred a growth
advantage in BJ/ ET cells expressing RasV12 (Figure 1E).
For further validation, we selected two hits: lncRNA#32,
which has one shRNA (shRNA3) at the top of the en-
richment list in all three replicates, and another shRNA
(shRNA2) giving minor enrichment; and lncRNA#30 with
two shRNAs (shRNA5 and shRNA3) showing consistent
enrichment in all three replicates (Figure 1E and Sup-
plementary Table S3). We validated the hits by repeating
the OIS experiment using individual shRNAs. We used an
shRNA targeting BRD7 (BRD7 shRNA4) as a positive
control, and two non-targeting shRNA as negative con-
trols. A proliferation assay (using BrdU labeling) indicated
bypass of oncogene-induced cellular arrest by one shRNA
(#30–5) targeting lncRNA#30 and two shRNAs (#32–2
and #32–3) targeting lncRNA#32 (Figure 2A and Supple-
mentary Figure S2A). To further examine the effect of loss-
of lncRNA#30 and #32 in OIS, we measured the induction
of senescence-associated -galactosidase (SA--Gal). In
comparison with negative control cells, a marked decrease
in SA--Gal was observed in RasV12-expressing BRD7-
knockdown (BRD7 kd), lncRNA#30–5 and lncRNA#32–
2 and #32–3 cells (Figure 2B and Supplementary Figure
S2B). In contrast, shRNA (#30–3) was not validated as ex-
pected from the screen outcome. Interestingly, RNA expres-
sion analysis indicated that only shRNAs#30–5, #32–2 and
#32–3 were effective toward their lncRNA targets, suggest-
ing on-target activity (Figure 2C and D). To exclude off-
target effects of the shRNAs, we designed additional vec-
tors targeting lncRNA#30 and #32 (Supplementary Table
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Figure 2. Functional validation of selected lncRNAs. (A) The proliferation of the various shRNA-transduced BJ-RASv12 cells was quantified using BrdU
assay, **P < 0.0005, two-tailed Student’s t-test. For every condition, the percentage of BrdU-positive cells was normalized to negative control cells. (B)
Senescent cells were quantified using SA--Gal assay, **P < 0.0005, two-tailed Student’s t-test. For every condition, the percentage of -gal-positive cells
was normalized to negative control cells. (C andD) qRT-PCR analysis of lncRNA#30 and #32 in the various shRNA-transduced cells treated with 4-OHT
relative to untreated cells. Data were normalized to a housekeeping gene and the levels in untreated cells was set to 1, **P < 0.0005, two-tailed Student’s
t-test. (E and F) Validation of additional shRNA-transduced BJ-RASv12 cells was performed as in panel A and B. BrdU (**P < 0.001) and SA--Gal
assays (**P< 0.0005) were quantified by two-tailed Student’s t-test. (G andH) qRT-PCR analysis of lncRNA #30 and #32 in the shRNA-transduced cells
presented in E and F. Data were normalized to a housekeeping gene and the levels in untreated cells was set to 1, **P< 0.0005, two-tailed Student’s t-test.
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S6), and repeated the proliferation and SA--Gal assays.
This experiment identified more functional shRNAs (#32–
8, #32–9) targeting lncRNA#32, but no additional shRNAs
targeting lncRNA#30 (Figure 2E and F; Supplementary
Figure S3A and B). qRT-PCR confirmed loss-of expres-
sion of lncRNA#32 by all four active shRNA vectors (#32–
2, 3, 8 and 9) (Figure 2H). In contrast, two new shRNAs
(#30–8, #30–9) showed efficient loss-of lncRNA#30 (Fig-
ure 2G) but did not induce bypass of OIS (Figure 2E and F;
Supplementary Figure S3A and B), indicating that the by-
pass of OIS by shRNA#30–5 was not mediated by its tar-
geted lncRNA. Altogether, these results demonstrate that
lncRNA#32 is both induced by oncogenic RAS and is re-
quired for the establishment of the OIS phenotype.
To further solidify the role of lncRNA#32 in OIS we
made use of a dual CRISPR-Cas9 system (61), and in-
duced deletions of the lncRNA#32 locus. As BJ cells do
not form single clones, generation of monoclonal popu-
lation of deleted cells was not possible. Instead, we per-
formed a functional genetic experiment to test whether the
cells containing the lncRNA#32 deletion are enriched in
cells undergoing OIS. Notably, Supplementary Figure S4A
shows that control-transduced BJ cells completely senesced,
p53 knockout BJ cells strongly bypassed OIS, and targeting
lncRNA#32 attenuated senescence, albeit to a lesser extent
than p53KO. To confirm that the dual CRISPR-Cas9 sys-
tem triggered deletion of lncRNA#32, we isolated genomic
DNA and performed semi-quantitative PCR to detect
lncRNA#32 with oligos (FW: TGGAGGGCTGAATCAT
CAAGTT,REV:ACTTCAAAGGGCAATTGCTGAAC)
surrounding the CRISPR-target region. While wild-type
and control-transduced cells produced only one band of
about 1.8 Kb, cells transduced with the lncRNA#32-
targeting vector showed lncRNA#32 deleted bands (∼350
bp), indicating the functionality of the CRISPR vector
(Supplementary Figure S4B). Intriguingly, the PCR signal
of the deletion band increased after 2 and 3 weeks fol-
lowing OIS induction, in line with a bypass of the OIS
phenotype. In comparison, no enrichment of the deleted
allele was noted following 3 weeks of culturing without
induction of OIS (Supplementary Figure S4B). This in-
dicates that lncRNA#32 deletion gives growth advantage
only under OIS conditions. As expected, we found by qRT-
PCR that cells expressing sgRNAs targeting lncRNA#32
have reduced level of lncRNA#32 (Supplementary Figure
S4C). Sanger sequencing confirmed the correct deletion of
lncRNA#32 (Supplementary Figure S4D). For simplicity
and in conjunction with its function, we hereafter refer to
lncRNA#32 as lncRNA-OIS1.
To extend our finding on the role of lncRNA-OIS1 inOIS
we employed a different cell system. We transduced all four
functional shRNAs targeting lncRNA-OIS1 (#32–2, 3, 8
and 9, which we renamed KD1, 2, 3 and 4, respectively)
into TIG3 cells expressing hTERT and 4-OH-tamoxifen
(4-OHT)-inducible oncogenic H-RasV12, and repeated the
BrdU labeling and SA--Gal experiments. First, q-RT-PCR
and GRO-seq analysis indicated upregulation of lncRNA-
OIS1 following oncogenic RAS induction (Supplementary
Figures S5E and S9A). Second, as expected, the introduc-
tion of all four lncRNA-OIS1 shRNAs reduced lncRNA-
OIS1 expression (Supplementary Figure S5E). Last, and
most profoundly, all four lncRNA-OIS1 shRNAs very ef-
fectively bypassed OIS as measured by the proliferation and
senescent assays BrdU and SA--Gal, respectively (Supple-
mentary Figure S5A–D). Altogether, our results demon-
strate that intact lncRNA-OIS1 is required for senescence
induction following RASV12 activation in primary human
cells.
Knockdown of lncRNA-OIS1 abolishes OIS gene expression
signature
Next, we sought to explore the mode of action of lncRNA-
OIS1 in senescence. To this goal, we first performed RNA-
seq of cells transduced with shRNAs against lncRNA-
OIS1, the positive controls p53 and BRD7, and negative
controls (Figure 3A). Comparison of gene expression pro-
files in negative controls and p53kd cells upon activation of
oncogenic RAS (the former enters senescence while the lat-
ter bypasses it) identified 885 differentially expressed genes
(386 up- and 499 downregulated in senescent cells) (Fig-
ure 3B). Functional enrichment analysis showed that the
set of genes whose expression was significantly repressed in
senescent cells (compared to the p53kd cells) was markedly
enriched for cell-cycle-related genes (Figure 3C), reflecting
the strong proliferation arrest that is imposed in negative
control cells upon oncogenic stress. This sharp downregu-
lation of cell-cycle genes defines a molecular signature that
characterizes the induction of the senescent physiological
state. Remarkably, knocking–down lncRNA-OIS1 signifi-
cantly abolished the repression of these genes (Figure 3D).
The effect observed for lncRNA-OIS1-kd was compara-
ble to the effect obtained by BRD7-kd but weaker than
the effect elicited by p53-kd (Figure 3D). In accordance
with the phenotypic effect of OIS-bypass, we observed that
lncRNA-OIS1-kd resulted in attenuation of the induction
of CDKN1A (p21), a prime target of p53 that is required
for OIS in BJ cells (Supplementary Figure S6A). We con-
firmed this result at the protein level using western blot
analysis (Figure 3E and Supplementary Figure S6B). We
included one shRNA (#32–6) which did not give knock-
down of lncRNA-OIS1 and showed no bypass of the senes-
cence phenotype (Figure 3E and Supplementary Figure
S6B) to demonstrate specificity of the decreased expression
of CDKN1A due to lncRNA-OIS1-kd.
To further characterize the effect of knocking-down
lncRNA-OIS1 on the cellular transcriptome, we systemati-
cally compared, using GSEA analysis (52), gene expression
profiles in cells induced for oncogenic RAS and transduced
either with shRNAs against lncRNA-OIS1 or with non-
targeting shRNAs. As expected from the phenotypic effect
and inline with the above analysis, the strongest gene sets
that were upregulated upon knocking-down lncRNA-OIS1
were related to proliferation and cell-cycle (Supplementary
Figure S6C). A set of genes that are induced in response
to ionizing irradiation was the most significantly downreg-
ulated gene set in the lncRNA-OIS1 kd cells. This set con-
tains numerous p53 direct target genes, indicating that at-
tenuated expression of lncRNA-OIS1 compromises the ac-
tivation of the p53 network (Supplementary Figure S6C).
In addition, genes of the oxidative phosphorylation path-
way are downregulated too in the lncRNA-OIS1 kd cells.
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Figure 3. LncRNA-OIS1 knockdown shows a gene expression signature characteristic of senescence bypass. (A) A scheme of the RNA-seq experiment.
RNA was collected from positive and negative control cells, and the various lncRNA-OIS1kd cells treated with 4-OHT for 14 days. Cells knocked-down
for p53 and BRD7 served as positive controls. (B) The comparison of gene expression profiles between p53kd and negative control cells, both treated with
4-OHT to induce oncogenic RAS, identified 885 differentially expressed genes. A total of 386 and 499 genes were up- and downregulated, respectively.
(C) Enriched functional categories in the set of genes that were downregulated in the senescent cells. As expected, the enriched categories are related to
cell proliferation and cell division. (D) For each of the conditions that we examined, we calculated the distribution of fold-change of expression for the
set of 135 cell-cycle genes whose expression is downregulated in senescence, relative to their expression in control untreated cells. In control cells, 4-OHT
treatment resulted in strong suppression of this set of genes (Ctr1, Ctr2 samples). In contrast, in lncRNA-OIS1-kd cells, the expression of these cell-cycle
genes was elevated compared to control cells. Notably, the effect observed in lncRNA-OIS1kds was similar to the effect of BRD7, but, as expected, weaker
than that of the p53kd. (E) CDKN1A protein levels examined by western blotting.
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Figure 4. LncRNA-OIS1 expression is required for the activation of DPP4 in response to oncogenic stress. (A) Subcellular localization of lncRNA-OIS1 in
BJ cells treated with or without 4-OHT. U2 and S14 RNAs were used as controls for nucleus and cytosol fractions, respectively. (B) ISH of lncRNA-OIS1
in BJ cells treated with or without 4-OHT. (C) Screenshots of GRO-seq data of the lncRNA-OIS1 and DPP4 genomic locus. R1 and R2 are two biological
replicates. (D) qRT-PCR analysis of DPP4 expression upon lncRNA-OIS1kd treated with or without 4-OHT, **P < 0.002, two-tailed Student’s t-test. (E)
DPP4 protein levels examined by western blotting.
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Figure 5. Induction of DPP4 is required for OIS. (A) qRT-PCR analysis of DPP4 expression uponDPP4kd (two different shRNAs) treated with or without
4-OHT, **P < 0.005, two-tailed Student’s t-test. (B) Western blot analysis of DPP4 protein. (C) BrdU proliferation analysis of DPP4kd BJ-RASv12 cells,
**P < 0.0005, two-tailed Student’s t-test. The percentage of BrdU-positive cells was normalized to negative control cells. (D) Senescence SA--Gal assay.
**P < 0.0005, two-tailed Student’s t-test. The percentage of -gal-positive cells was normalized to negative control cells.
Notably, all these gene sets show the opposite response in
cells that enter senescence in response to oncogenic stress
(Supplementary Figure S6C), demonstrating that loss of
lncRNA-OIS1 abolishes OIS gene expression signature.
Loss-of lncRNA-OIS1 compromises the induction of DPP4
by OIS
To investigate themechanism(s) bywhich lncRNA-OIS1 af-
fects OIS induction, we first examined its subcellular local-
ization. In control BJ/ET/RasV12ER cells, lncRNA-OIS1
was located both in the nucleus and the cytosol. Follow-
ing RASV12 activation, lncRNA-OIS1 maintained a similar
pattern in these two compartments (Figure 4A). ISH analy-
sis confirmed lncRNA-OIS1 increased expression following
RASV12 induction, and its localization in the nucleus and
cytosol. Loss-of lncRNA-OIS1 confirmed the specificity of
the signal to lncRNA-OIS1 (Figure 4B).
LncRNAs can impact the expression of nearby genes
on the chromatin (cis function), or affect gene expres-
sion in trans (for example by controlling mRNA tran-
scription, splicing and translation). We therefore first in-
terrogated whether lncRNA-OIS1 functions in trans, and
whether ectopic expression of lncRNA-OIS1 can drive cells
into senescence without RAS induction. We over-expressed
lncRNA-OIS1 in primary BJ cells (full length or exons;
Supplementary Figure S7A), but observed no induction of
senescence as measured by BrdU labeling and SA--Gal
assays (Supplementary Figure S7B–D). Second, we over-
expressed lncRNA-OIS1 (both full length and exons) in
lncRNA-OIS1-kd cells to test whether ectopic expression of
lncRNA-OIS1 can restore the senescence phenotype. How-
ever, despite the high expression of lncRNA-OIS1 (Sup-
plementary Figure S8A), OIS-bypass by lncRNA-OIS1-
kd was maintained (Supplementary Figure S8B–D). These
data indicated that lncRNA-OIS1 does not function in
trans, rather, a localized expression and effect on neighbor-
ing genes is required (cis effect).
In general, lncRNAs can be physically linked to the lo-
cus from which they are encoded, and exert its function
during transcription without the need for processing or
shuttling. Well-studied examples of cis-acting lncRNAs are
those that cause X-inactivation (62,63). Examples of other
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Figure 6. Ectopic expression ofDPP4 induces senescence in lncRNA-OIS1kd cells. (A) BrdU proliferation assay ofDPP4 or vector-transduced BJ-RASv12-
lncRNA-OIS1kd cells. **P< 0.001, two-tailed Student’s t-test. The percentage of BrdU-positive cells was normalized to negative control cells. (B) SA--Gal
assay. **P < 0.001, two-tailed Student’s t-test. The percentage of -gal-positive cells was normalized to negative control cells. (C) Western blot analysis of
DPP4 protein. (D) TCGA data analysis of lncRNA-OIS1 and DPP4 expression in PRAD samples (r = 0.469, P-value = 2.5e−31).
cis-regulatory lncRNAs include ncRNA-a1–7, Hottip and
Mistral, the perturbation of which lead to decreased ex-
pression of nearby genes (64–67), suggesting that gene reg-
ulation in cis is a very important mode of lncRNA ac-
tion. To investigate whether lncRNA-OIS1 expression influ-
ences nearby genes, we analyzed Global Run-On Sequenc-
ing data (GRO-Seq) of senescent and proliferation BJ cells
(55). We observed that both lncRNA-OIS1 and its nearby
gene DPP4 were increased in the BJ cells upon RAS in-
duction (Figure 4C). We also observed the same effect in
TIG3 cells (Supplementary Figure S9A). Additionally, loss-
of lncRNA-OIS1 abolished the activation of DPP4 follow-
ing oncogene induction based on BJ cells RNA-seq data
(Supplementary Figure S9B). We solidified these results by
qRT-PCR (Figure 4D and Supplementary Figure S9C) and
chose the best two lncRNA-OIS1 knockdowns (KD2 and 4)
for western blot analyses of DPP4 expression four days fol-
lowing RASV12 induction, before the cell-cycle is arrested
and senescence is established (Figure 4D and E). Indeed,
attenuated activation of DPP4 protein expression was ob-
tained in cells with lncRNA-OIS knockdown. A similar ef-
fect was also observed in TIG3 lncRNA-OIS1-kd cells 4
days following RASV12 induction (Supplementary Figure
S9D). Altogether, these data link lncRNA-OIS1 to regula-
tion of DPP4 expression and to the senescent phenotype in-
duced by oncogenic RAS.
Loss-of DPP4 bypasses OIS
Interestingly, it has been reported that DPP4 is a tumor
suppressor in melanoma (68,69), non-small cell lung cancer
(70), ovarian cancer (71–73), endometrial carcinoma (74),
prostate cancer (75), neuroblastoma (76) and glioma (77).
We therefore hypothesized that the tumor suppressive role
of DPP4 is linked to OIS. To examine this issue, we gener-
ated shRNAs (Supplementary Table S7) transduced DPP4
knockdown BJ cells. qRT-PCR and western blot analyses
confirmed significant reduction of DPP4 mRNA and pro-
tein levels upon knockdown (Figure 5A and B). As pre-
dicted, loss-of DPP4 bypassed OIS, as determined by pro-
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Figure 7. Schematic representation of lncRNA-OIS1 function in normal and senescence conditions.
liferation and SA--Gal assays (Figure 5C and D; Supple-
mentary Figure S9E). Next, we examinedwhether lncRNA-
OIS1 regulates senescence through DPP4.We cloned DPP4
in a lentiviral vector, ectopically expressed it in lncRNA-
OIS1-kd cells and induced OIS. Intriguingly, proliferation
(BrdU labeling) and SA--Gal assays demonstrated that ec-
topic expression of DPP4 abolished the senescence bypass
phenotype of lncRNA-OIS1-kd cells, while a control vector
did not (Figure 6A and B; Supplementary Figure S10A and
B). We confirmed the overexpression of DPP4 by western
blot (Figure 6C and Supplementary Figure S10C). These
experiments indicate that DPP4 is the relevant target gene
of lncRNA-OIS1 during OIS, and that lncRNA-OIS1 is a
major determinant of DPP4 function in OIS.
Association of LncRNA-OIS1and DPP4 in the tumors
Last, we interrogated lncRNA-OIS1 expression in tumors
and its correlation with that of DPP4 by analyzing TCGA
data. LncRNA-OIS1 is very lowly expressed in most tu-
mor types (Supplementary Figure S11A). We plotted the
read counts of the lncRNA-OIS1 among normal and tu-
mor samples, indicating in each type the number of samples
with at least one read count for lncRNA-OIS1. Interest-
ingly, prostate adenocarcinoma (PRAD) samples showed
clear lncRNA-OIS1 expression. Using this dataset for dif-
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ferential expression analysis, we observed no change be-
tween tumor and normal samples (empirical Bayes test, B
= −5.79, P-value = 0.28) (Supplementary Table S4), but a
significant positive correlation between lncRNA-OIS1 and
DPP4 expression in the tumor samples (r = 0.469, P-value
= 2.5e−31) (Figure 6D), suggesting that at least in PRAD
DPP4 expression is controlled by lncRNA-OIS1.
DISCUSSION
Over the past few years, numerous lncRNAs have been dis-
covered and characterized as critical factors in physiologi-
cal and pathological processes. However, the role of lncR-
NAs in OIS remained unexplored. Here, we contribute to
the understanding of the function of lncRNAs by describ-
ing a role of lncRNA-OIS1 in cellular senescence provoked
by the expression of oncogenic RAS (OIS). Upregulation
of lncRNA-OIS1 following OIS was required for the induc-
tion of DPP4, a well-described gene with tumor suppressive
activity. Differential gene expression analyses of lncRNA-
OIS1 knockdown cells indicated attenuated activation of
CDKN1A followingOIS induction, and confirmed changes
in cell-cycle regulatory genes favoring cellular proliferation.
Gene complementation experiments indicated that DPP4,
a lncRNA-OIS1 neighboring gene, is the downstream tar-
get of lncRNA-OIS1 in senescence. Exactly how DPP4 af-
fects CDKN1A and cell-cycle genes, and how lncRNA-
OIS1 controls DPP4 expression, remains to be uncovered.
Nevertheless, we describe here an important function of
lncRNAs with potentially influential implications in cancer
biology.
OIS is a major senescence type and it poses a critical bar-
rier to cancer. A recent study has shown that the lncRNA-
MIR31HG was a senescence modulator during BRAF-
V600 induced senescence in TIG3 cells (46). It has also been
shown that loss-of MIR31HG reduces cell growth and pro-
motes a strong senescence phenotype through the regula-
tion of the tumor suppressor P16INK4A. Here, we add to
this knowledge by identifying and characterizing the role of
lncRNA-OIS1 in regulating senescence through the control
of a nearby gene DPP4.
Interestingly, we also overexpressed lncRNA-OIS1 in BJ
cells to examine whether high levels of the lncRNA-OIS1
can drive cells into senescence. However, we neither ob-
served senescence induction nor DPP4 was activated (Sup-
plementary Figure S7). Additionally, also the ectopic ex-
pression of lncRNA-OIS1 was not able to revert the bypass
of senescence and the reduced DPP4 activation induced by
lncRNA-OIS1 knockdown under OIS (Supplementary Fig-
ure S8). This is indicative of a cis function of lncRNA-OIS1.
Indeed, we identified DPP4, a nearby gene to lncRNA-
OIS1, as a key component of OIS. First, loss-of DPP4, sim-
ilar to lncRNA-OIS1 loss, resulted in bypass of senescence
(Figure 5). Second, ectopic expression of DPP4 reverted the
bypass of senescence induced by the loss-of lncRNA-OIS1
(Figure 6A–C and Supplementary Figure S10). Addition-
ally, a recent research found that DPP4 can regulate senes-
cence in WI-38 cells, strongly supporting our observations
(78). However, although both lncRNA-OIS1 and DPP4
genes reside in the same topologically associating chromatin
domain through a CCCTC-binding factor (CTCF) loop
(Supplementary Figure S12A), and chromatin loops can be
identified in various ChIA-PET and Hi-C chromatin con-
formation capture datasets (Supplementary Figure S12B),
we did not observe a clear direct interaction of lncRNA-
OIS1 locus with the promoter of DPP4 using 4C, a chro-
matin capture analysis technique, through two distinct view
point sites (Supplementary Figure S13A). Thus, how ex-
actly the expression of DPP4 depends on lncRNA-OIS1
remains unclear. We speculate that lncRNA-OIS1 expres-
sion may be required to allow high chromatin accessibil-
ity to senescence-associated DPP4-activating transcription
factors by directly recruiting essential transcription factors,
or alternatively by counteracting chromatin-repressive com-
ponents of the chromatin (Figure 7). Nevertheless, our find-
ings here elucidate the importance of lncRNA-OIS1 for elic-
iting a proper cellular response to the emergence of onco-
genic stress.
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